March 9, 2026BMC Cardiovascular Disorders0 citationsOpen Access

Clinical efficacy and safety of recombinant human brain natriuretic peptide in the treatment of sepsis complicated by heart failure: a systematic review and meta-analysis

Q: What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: Sepsis complicated by heart failure (SCHF) (n=1182). Intervention: Recombinant human brain natriuretic peptide (rhBNP) vs. Conventional Western therapy (CWT). Primary outcome: 28-day mortality (RR 0.73, 95% CI 0.58-0.92, p=0.006).

WLWei LiuGuangzhou University of Chinese Medicine WQWenjie QiuGuangzhou University of Chinese Medicine ZZZhilin ZhangGuangzhou University of Chinese Medicine

Key Result

Recombinant human brain natriuretic peptide combined with conventional therapy significantly reduced 28-day mortality (RR 0.73) in patients with sepsis complicated by heart failure.

Key Points

This study aims to assess the effectiveness and safety of recombinant human brain natriuretic peptide in sepsis complicated by heart failure.
Conducted a systematic review and meta-analysis of RCTs
Searched 8 databases for relevant trials
Included ten Chinese RCTs with 1,182 patients
Measured primary outcomes like 28-day mortality and left ventricular ejection fraction
Utilized Trial Sequential Analysis and the GRADE framework for quality assessment.
RhBNP reduced 28-day mortality (RR = 0.73)
Improved left ventricular ejection fraction by 4.91
Increased total clinical effective rate (RR = 1.26)
Enhanced cardiac output by 0.47
No significant difference in adverse events (RR = 0.77).

Study Design

Type

Meta-Analysis (n=1,182)

Structured PICO

Does recombinant human brain natriuretic peptide (rhBNP) combined with conventional Western therapy reduce 28-day mortality and improve LVEF in adult patients with sepsis complicated by heart failure?

Population

1,182 adult patients with sepsis complicated by heart failure from 10 Chinese randomized controlled trials, evaluated for 28-day mortality and cardiac function.

Intervention

Recombinant human brain natriuretic peptide (rhBNP) combined with conventional Western therapy (CWT)

Comparator

Conventional Western therapy (CWT) alone (encompassing infection source control, antimicrobial treatment, fluid resuscitation, vasopressors, corticosteroids, inotropic support, blood product transfusion, sedative and analgesic management, glycemic control, mechanical ventilation, renal replacement therapy, and nutritional support)

Outcome

28-day mortality and left ventricular ejection fraction (LVEF)hard clinical

Adjunctive rhBNP may offer survival and cardiac function benefits in sepsis complicated by heart failure, though current evidence is of low certainty and requires confirmation by larger, multinational RCTs.

Main Result

Relative Risk: 0.73 (95% CI 0.58–0.92)

p-value: p=0.006

Limitations

Evidence is of very low certainty for 28-day mortality and LVEF
Findings are non-generalizable as all included trials were conducted in China
Safety concerns persist as rhBNP did not significantly reduce adverse events
Inconsistent reporting across trials precluded uniform distinction between treatment-related and all-cause adverse events
Variability in category definitions for total clinical effective rate across studies limits comparability

Abstract

Heart failure is among the most prevalent organ dysfunctions in sepsis and carries a high mortality rate. Currently, no specific drugs are available. Recombinant human brain natriuretic peptide (rhBNP) has demonstrated efficacy in treating isolated heart failure. This study aims to evaluate the feasibility of using rhBNP in the management of sepsis complicated by heart failure (SCHF). Eight databases were searched for qualified randomized controlled trials (RCTs) from inception to 19 July 2025, with no language restrictions. The primary outcomes included 28-day mortality and left ventricular ejection fraction (LVEF). The secondary outcomes included total clinical effective rate (TCER), APACHE II scores, cardiac output (CO), and adverse events (AEs). The meta-analyses were conducted by R (version 4.5.0). We utilized the Trial Sequential Analysis (TSA) software to perform TSA. Subsequently, the quality of the evidence was assessed using the GRADE framework (the Grading of Recommendation, Assessment, Development, and Evaluation system). This study was registered with PROSPERO (CRD 42023491344). Ten Chinese RCTs involving 1,182 patients were included. Pooled analysis showed that rhBNP combined with conventional Western therapy (CWT) was associated with reduced 28-day mortality (RR = 0.73, 95% CI: 0.58–0.92, p = 0.006) and APACHE II scores (MD = -4.18, 95% CI: -7.80 to -0.55, p = 0.024), and improved TCER (RR = 1.26, 95% CI: 1.12–1.41, p < 0.0001), LVEF (MD = 4.91, 95% CI: 2.56–7.26, p < 0.0001), and CO (MD = 0.47, 95% CI: 0.21–0.74, p = 0.0005). However, rhBNP did not significantly reduce AEs (RR = 0.77, 95% CI: 0.54–1.08, p = 0.13). The certainty of evidence was graded as low for CO and AEs, and very low for 28‑day mortality, LVEF, TCER, and APACHE II scores. Adjunctive rhBNP may offer cardiac and survival benefits in sepsis complicated by heart failure, but the evidence is of low certainty, non‑generalizable, and safety concerns persist. These hypothesis‑generating findings require confirmation by rigorously designed, multinational RCTs.

Ask AI

Helpful

Bookmark

View Full Paper